Vascular channels formed by subpopulations of PECAM1 + melanoma cells

Nature Communications

Volumn 5, Issue , 2014, Pages

  Dunleavey, James M ^a   Xiao, Lin ^a   Thompson, Joshua ^a   Kim, Mi Mi ^a   Shields, Janiel M ^b   Shelton, Sarah E ^c   Irvin, David M ^b   Brings, Victoria E ^a   Ollila, David W ^a   Brekken, Rolf A ^d   Dayton, Paul A ^c   Melero Martin, Juan M ^e   Dudley, Andrew C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Biomedical Research Imaging Center   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CD31 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 ALPHA; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; GREEN FLUORESCENT PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN A;

ADHESION; CANCER; CELLS AND CELL COMPONENTS; CLONAL GROWTH; GENETIC ANALYSIS; MIMICRY; RODENT; SENSORY SYSTEM; SUBPOPULATION; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL SUBPOPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; MOUSE; NEURAL CREST; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; EXPERIMENTAL MELANOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SKIN TUMOR; TUMOR CELL LINE;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-2; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84920135434     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6200     Document Type: Article

References (60)

1. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175, 409-416 (1972).
2. Cao, Y. et al. Forty-year journey of angiogenesis translational research. Sci Transl. Med. 3, 114rv3 (2011).
3. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
4. Ellis, L. M. & Hicklin, D. J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 14, 6371-6375 (2008).
5. Ellis, L. M. & Fidler, I. J. Finding the tumor copycat. Therapy fails, patients don't. Nature Med. 16, 974-975 (2010).
6. Dudley, A. C. Tumor endothelial cells. Cold Spring Harb. Perspect. Med. 2, a006536 (2012).
7. Dunleavey, J. M. & Dudley, A. C. Vascular mimicry: concepts and implications for anti-angiogenic therapy. Curr. Angiogenesis 1, 133-138 (2012).
8. Dudley, A. C. et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 14, 201-211 (2008).
9. Ghosh, K. et al. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl Acad. Sci. 105, 11305-11310 (2008).
10. St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).
11. Hida, K. et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64, 8249-8255 (2004).
12. Hellebrekers, D. M. E. I. et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 67, 4138-4148 (2007).
13. Soda, Y. et al. From the Cover: Feature Article: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl Acad. Sci. USA 108, 4274-4280 (2011).
14. Ricci-Vitiani, L., Pallini, R., Biffoni, M. & Todaro, M. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828 (2010).
15. Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833 (2010).
16. Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752 (1999).
17. van der Schaft, D. W. J. Tumor cell plasticity in ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 65, 11520-11528 (2005).
18. Pardali, E. et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 30, 334-345 (2011).
19. Cheng, L. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139-152 (2013).
20. Sood, A. K. et al. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 158, 1279-1288 (2001).
21. Harrell, J. C. et al. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin. Exp. Metastasis 31, 33-45 (2014).
22. Lai, C. Y., Schwartz, B. E. & Hsu, M. Y. CD133 melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 72, 5111-5118 (2012).
23. Seftor, R. E. B. et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 181, 1115-1125 (2012).
24. McDonald, D. M., Munn, L. & Jain, R. K. Vasculogenic mimicry: how convincing, how novel, and how significant? Am. J. Pathol. 156, 383-388 (2000).
25. van Beijnum, J. R., Rousch, M., Castermans, K., van der Linden, E. & Griffioen, A. W. Isolation of endothelial cells from fresh tissues. Nat. Protoc. 3, 1085-1091 (2008).
26. Hendrix, M. J. C., Seftor, E. A., Hess, A. R. & Seftor, R. E. B. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer. 3, 411-421 (2003).
27. Francescone, R. et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J. Biol. Chem. 287, 24821-24831 (2012).
28. Xiao, L., Harrell, J. C., Perou, C. M. & Dudley, A. C. Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro. Angiogenesis 17, 511-518 (2013).
29. Kendal, W. S., Wang, R. Y., Hsu, T. C. & Frost, P. Rate of generation of major karyotypic abnormalities in relationship to the metastatic potential of B16 murine melanoma. Cancer Res. 47, 3835-3841 (1987).
30. Hu, F. N., Wang, R. Y. & Hsu, T. C. Clonal origin of metastasis in B16 murine melanoma: A cytogenetic study. J. Natl Cancer Inst. 78, 155-163 (1987).
31. DeLisser, H. M. et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am. J. Pathol. 151, 671-677 (1997).
32. Cao, G. et al. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am. J. Physiol. Cell Physiol. 282, C1181-C1190 (2002).
33. DeLisser, H. et al. Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc. Natl Acad. Sci. USA 107, 18616-18621 (2010).
34. Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552 (2009).
35. Hanna, S. C. et al. HIF1a and HIF2a independently activate SRC to promote melanoma metastases. J. Clin. Invest. 123, 2078-2093 (2013).
36. Eyles, J. et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030-2039 (2010).
37. Gessner, R. C., Aylward, S. R. & Dayton, P. A. Mapping microvasculature with acoustic angiography yields quantifiable differences between healthy and tumor-bearing tissue volumes in a rodent model. Radiology 264, 733-740 (2012).
38. Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246 (2006).
39. Gumina, R. J., Kirschbaum, N. E., Piotrowski, K. & Newman, P. J. Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity. Blood 89, 1260-1269 (1997).
40. Roland, C. L. et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 8, 1761-1771 (2009).
41. Sullivan, L. A. et al. r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS ONE 5, e12031 (2010).
42. Carson, C. et al. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res. 25, 514-526 (2012).
43. Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018-8023 (2001).
44. Huang, S., Jean, D., Luca, M., Tainsky, M. A. & Bar-Eli, M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 17, 4358-4369 (1998).
45. Jean, D. et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J. Biol. Chem. 273, 16501-16508 (1998).
46. Karjalainen, J. M., Kellokoski, J. K., Eskelinen, M. J., Alhava, E. M. & Kosma, V. M. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J. Clin. Oncol. 16, 3584-3591 (1998).
47. Pellikainen, J. et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin. Cancer Res. 8, 3487-3495 (2002).
48. Warren, B. A. & Shubik, P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab. Invest. 15, 464-478 (1966).
49. McDonald, D. M. & Choyke, P. L. Imaging of angiogenesis: from microscope to clinic. Nature Med. 9, 713-725 (2003).
50. Yang, S., Graham, J., Kahn, J. W., Schwartz, E. A. & Gerritsen, M. E. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am. J. Pathol. 155, 887-895 (1999).
51. Dejana, E., Orsenigo, F., Molendini, C., Baluk, P. & McDonald, D. M. Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees. Cell Tissue Res. 335, 17-25 (2009).
52. Chang, Y. S. et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. USA 97, 14608-14613 (2000).
53. Di Tomaso, E. et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 65, 5740-5749 (2005).
54. Sun, J. et al. Contributions of the extracellular and cytoplasmic domains of platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) in regulating cell-cell localization. J. Cell Sci. 113(Pt 8): 1459-1469 (2000).
55. Tang, D. G., Chen, Y. Q., Newman, P. J., Shi, L. & Gao, X. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J. Biol. Chem. 268, 22883-22894 (1993).
56. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Med. 18, 883-891 (2012).
57. Dudley, A. C. et al. Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood 116, 3367-3371 (2010).
58. Streeter, J. E., Gessner, R., Miles, I. & Dayton, P. A. Improving sensitivity in ultrasound molecular imaging by tailoring contrast agent size distribution: in vivo studies. Mol. Imaging. 9, 87-95 (2010).
59. Kogan, P. et al. Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion. Ultrasound. Med. Biol. 37, 900-908 (2011).
60. Roland, C. L. et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE 4, e7669 (2009).